%D8%AC%D9%8A%D9%85%D8%AA%D9%88%D8%B2%D9%88%D9%85%D8%A7%D8%A8_%D8%A3%D9%88%D8%B2%D9%88%D8%BA%D8%A7%D9%85%D9%8A%D8%B3%D9%8A%D9%86Gemtuzumab-OzogamicinGemtuzumab_ozogamicin%D8%AC%D9%85%D8%AA%D9%88%D8%B2%D9%88%D9%85%D8%A8_%D8%A7%D9%88%D8%B2%D9%88%DA%AF%D8%A7%D9%85%DB%8C%D8%B3%DB%8C%D9%86Gemtuzumab_ozogamicineGemtuzumab_ozogamicin%E3%82%B2%E3%83%A0%E3%83%84%E3%82%BA%E3%83%9E%E3%83%96_%E3%82%AA%E3%82%BE%E3%82%AC%E3%83%9E%E3%82%A4%E3%82%B7%E3%83%B3Gemtuzumab_ozogamycynyGentuzumab_ozogamicinaGemtuzumab_ozogamicinGemtuzumab_ozogamicinQ412685
about
P3781
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesCombination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid LeukemiaS9031-9333-0106-0112-A Study of Biomarkers in Samples From Patients With Acute Myeloid Leukemia Treated With Standard Chemotherapy With or Without Gemtuzumab OzogamicinEfficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate RiskFractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Participants With Acute Myeloid LeukemiaGemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid LeukemiaS0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AMLGemtuzumab Ozogamicin in Treating Patients With Acute Myeloid LeukemiaAtovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)Pfizer Immunotherapy Combinations for Acute Myeloid Leukemia (AML) Multi-Arm Study 1Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene MutationTesting the Combination of Standard Induction Therapy With Gemtuzumab Ozogamicin and Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid LeukemiaPracinostat in Combination With Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AMLLiposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic SyndromeDexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood CancersCPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid LeukemiaTretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic LeukemiaStudy of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531Biomarkers in DNA Samples From Younger Patients With Newly Diagnosed Acute Myeloid Leukemia Receiving Gemtuzumab OzogamicinVorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid LeukemiaVorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaAllogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMMLVorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AMLCPX-351+GO in Subjects 55 Years Old, or Older, With AMLAzacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaExpanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative TherapyTrial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy CombinationsImmunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDSDNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AMLAllogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk LeukemiaLAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular RemissionDecitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic SyndromeA Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years OldInduction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeSCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
P4844
Q61920712-09E14A2F-581E-4106-BB6E-C1FEAB3CC73FQ61932952-F7AF70E1-42C0-409B-A01E-5AA6820BE6F8Q61957399-8FCB24C6-5485-4699-919E-1A69AC72D8DCQ61981483-489FE1DA-4CE1-4209-8E16-7FB1D7C40EF0Q62035353-6FB6B749-4221-489D-BC52-619F0F112FADQ62110095-89005B18-4623-450D-A512-CF80AC9F94B9Q62110646-1868BE2D-CD63-42CF-B04B-560B8DAFB6D1Q63316282-7CEF68D0-8EE0-4AA2-895F-3A433AC2FFBCQ63397688-C25D73E0-C5EB-4FCA-8F3D-3FEE8D6F2AC4Q63405275-2ABAED02-35CA-4FDC-8366-BFDCF27D703BQ63576784-859DA8C3-B680-4474-BA7F-8B75927E6E51Q63578748-70E5F883-9A93-4ED4-8E69-A5DAC19B3B81Q63587346-30BEA094-1E98-4B96-A9A8-6FED5952CE92Q63596848-AE8A92DF-4A8B-4AA7-89A6-4622919AF52EQ63598098-874519A9-D3C7-44A5-9B72-926441455991Q63599929-8BE891C2-BCE1-4D90-8239-BC8D9D24DCB2Q63805809-2ADB228E-1189-4323-8AF0-3C037A789954Q63806558-E727F189-BB99-42E8-A03F-8B8E86DF556BQ63806678-977EB153-281F-4467-94C5-48ABA510D4A0Q63833058-3E119246-E7E4-42A0-A4CF-C6293F3FB2F1Q63834153-93BBB0AE-8B35-40B1-BE8B-04CD39A35F62Q64047285-1B5DCB30-14EE-4F8F-855D-1D9DF99E6B53Q64047934-C0FEC78C-C78C-4CAF-B677-DC418D9C117FQ64170895-78147098-610D-415D-99EF-17F41C3575CCQ64188053-99C5B22E-CF30-43F6-ABE4-EEB3596C8627Q64188774-151B3C4D-606B-4E58-BFBE-126E9FAFCE56Q64597718-7DD30768-3961-41D5-B530-7AA9905A3311Q64601212-7221067E-36C4-4999-B011-EE9ABAB670BEQ64604309-B4E37D2D-5127-4046-9C21-542617FCAC8AQ64608644-0E80D512-F7BF-4CC9-AE7C-F92212ADB7DDQ64658496-AE6382BE-16E5-4B20-9B0C-6A00C5A722A2Q64659275-6BC0CCF0-4EB6-4E7F-BC8E-DB6914063FBAQ64663472-1C6B81E2-E933-4431-8ABA-09EB20C4E869Q64664379-4A72515F-F1D3-40A2-8C94-4FAA3EAA1FDBQ64673985-38814C50-C4A8-4257-B0BB-9E7F8BE3A7D7Q64675492-67668F55-7617-4ED0-9A63-9EAE63A98F87Q64679596-E0474DBA-259E-40F1-AEBC-FB09C66B2A51Q64709009-F836C406-6F99-4FF2-8351-2802A889E876Q64709267-A3D1BF44-5E91-43AA-AD2B-EE373D8F9FDCQ64716589-756DBAFA-ABE6-4E86-B34B-64CE7A7E2336
P4844
description
Protein
@de
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Gemtuzumab ozogamicin
@en
Gemtuzumab ozogamicin
@it
Gemtuzumab ozogamicin
@nl
Gemtuzumab ozogamicin
@sh
Gemtuzumab ozogamicin
@sr
Gemtuzumab
@pl
Gemtuzumab-Ozogamicin
@de
Gentuzumab ozogamicina
@pt
gemtuzumab ozogamicin
@fr
gemtuzumabozogamicin
@nn
type
label
Gemtuzumab ozogamicin
@en
Gemtuzumab ozogamicin
@it
Gemtuzumab ozogamicin
@nl
Gemtuzumab ozogamicin
@sh
Gemtuzumab ozogamicin
@sr
Gemtuzumab
@pl
Gemtuzumab-Ozogamicin
@de
Gentuzumab ozogamicina
@pt
gemtuzumab ozogamicin
@fr
gemtuzumabozogamicin
@nn
altLabel
CDP-771
@en
CMA-676
@en
CMC-676
@en
Gemtuzumab ozogamicin
@de
Gemtuzumab
@de
Mylotarg
@pt
WAY-CMA-676
@en
prefLabel
Gemtuzumab ozogamicin
@en
Gemtuzumab ozogamicin
@it
Gemtuzumab ozogamicin
@nl
Gemtuzumab ozogamicin
@sh
Gemtuzumab ozogamicin
@sr
Gemtuzumab
@pl
Gemtuzumab-Ozogamicin
@de
Gentuzumab ozogamicina
@pt
gemtuzumab ozogamicin
@fr
gemtuzumabozogamicin
@nn
P31
P2153
P592
P6366
P646
P665
P2067
P2115
N0000023004
P2153
P2275
Gemtuzumab ozogamicin
@en
P231
220578-59-6
P267
P3345
P3780
P592
CHEMBL1201506
P6366
2778623314
P646
P652
8GZG754X6M
P665
P7830
GemtuzumabOzogamicin